We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




High-Sensitivity Version of Common Blood Test May Predict Early Onset of Hypertension

By LabMedica International staff writers
Posted on 02 Sep 2015
A study analyzing blood samples from over 5,000 people suggests that a more sensitive version of the standard blood test for cardiac troponin T (CT-T)—long used to verify heart muscle damage from heart attacks—could help identify people on the verge of developing hypertension well before it can be detected with a blood pressure machine.

High blood pressure’s stealthy onset, its variability over time, and the need to re-check over multiple visits before making a diagnosis, have hampered efforts to treat and prevent this disease. More...
Results of the new study using a high-sensitivity CT-T test, led by Johns Hopkins University (Baltimore, MD, USA) investigators, showed that people with subtle elevations in CT-T — below levels detectable with the standard test — were more likely to be diagnosed with hypertension within a few years. The test could also identify those at risk for left ventricular hypertrophy, the abnormal thickening of the lower left chamber of the heart, a common consequence of untreated high blood pressure. Therefore, subtle increase in CT-T levels may have value as a marker predicting high blood pressure and subclinical heart damage.

“Identifying those at risk for hypertension as well as those in the earliest stages of the disease would allow us to intervene much sooner, either with lifestyle changes or medication, before the condition develops fully and has had a chance to damage organs,” said first author Bill McEvoy, MBBCh, MHS, assistant professor at the Johns Hopkins University School of Medicine.

The standard CT-T test is relatively inexpensive (USD 10–20) and is the gold-standard test for cardiac muscle damage from recent or ongoing heart attacks, indicating whether someone with chest pain or other cardiac symptoms is having a heart attack. However results are often “normal” for many with other forms of cardiac damage unrelated to heart attacks. The new version is calibrated to detect far lower CT-T levels, even trace amounts released by heart cells injured by spikes in blood pressure that come and go unnoticed, often for years. It is currently used across Europe, but not yet available for clinical use in the USA.

“Our data suggest that the high-sensitivity CT-T test could flag people with normal blood pressure in the doctor’s office who are at high risk for hypertension and other poor outcomes,” said senior study investigator Elizabeth Selvin, PhD, MPH, professor at Johns Hopkins Bloomberg School of Public Health. For example, people whose blood pressures yo-yo during the day or those whose pressures don’t decrease as normal during sleep, can be missed during regular blood pressure checks. Such people are prone to developing silent heart damage from erratic blood pressure and often progress to hypertension within a few years. “That group may benefit from more aggressive monitoring, including a 24-hour blood pressure monitor,” said Prof. Selvin.

If further clinical trials affirm the reliability of the high-sensitivity CT-T test as a screening tool for subclinical or future hypertension, it could also help clinicians ward off other devastating complications, including kidney brain and eye damage.

The summary of the findings, by McEvoy JW et al., were published online ahead of print July 7, 2015, in the journal Circulation.

Related Links:

Johns Hopkins University



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.